Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Malignant Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05076695
What this trial is testing

Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-positive Breast Cancer
Fudan University 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT03879577
What this trial is testing

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Who this might be right for
Breast CancerBreast Cancer FemaleHER2-positive Breast Cancer+2 more
University of Chicago 53
Early research (Phase 1)UnknownNCT04450732
What this trial is testing

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Biliary Tract CancerHER2-Positive Salivary Gland Carcinomas+1 more
GeneQuantum Healthcare (Suzhou) Co., Ltd. 96
Testing effectiveness (Phase 2)Study completedNCT04539938
What this trial is testing

Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer 70
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07178938
What this trial is testing

Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases

Who this might be right for
Solid TumorsHER2-positive Breast Cancer
MedSIR 10
Large-scale testing (Phase 3)Study completedNCT06107790
What this trial is testing

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Zhejiang Hisun Pharmaceutical Co. Ltd. 570
Not applicableLooking for participantsNCT05406635
What this trial is testing

Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer

Who this might be right for
CardiotoxicityHER2-positive Breast Cancer
Odense University Hospital 220
Large-scale testing (Phase 3)Study completedNCT01583426
What this trial is testing

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)

Who this might be right for
Tubular Breast Cancer Stage IIMucinous Breast Cancer Stage IIBreast Cancer Female NOS+5 more
GBG Forschungs GmbH 1,229
Not applicableUnknownNCT04011085
What this trial is testing

Tw HER2 Positive Breast Cancer Productivity & Utility Study

Who this might be right for
HER2-positive Breast Cancer
Taiwan Epidemiology Association 300
Testing effectiveness (Phase 2)Ended earlyNCT06844669
What this trial is testing

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Who this might be right for
HER2-positive Breast CancerHER2+ Breast Cancer
Washington University School of Medicine 7
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07716046
What this trial is testing

Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast CancerHormone Receptor-positive Breast Cancer+1 more
Fudan University 240
Testing effectiveness (Phase 2)Study completedNCT00841828
What this trial is testing

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 102
Testing effectiveness (Phase 2)Active Not RecruitingNCT04588545
What this trial is testing

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Who this might be right for
HER2-positive Breast CancerLeptomeningeal MetastasisLeptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute 33
Post-approval studies (Phase 4)Study completedNCT01301729
What this trial is testing

Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Who this might be right for
Breast Cancer
Hoffmann-La Roche 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT06157892
What this trial is testing

Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Who this might be right for
Breast NeoplasmsGastroesophageal Junction AdenocarcinomaHER2 Low Breast Neoplasms+7 more
Seagen, a wholly owned subsidiary of Pfizer 54
Large-scale testing (Phase 3)Active Not RecruitingNCT06265428
What this trial is testing

Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
DualityBio Inc. 228
Early research (Phase 1)Looking for participantsNCT06253871
What this trial is testing

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Who this might be right for
HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more
Iambic Therapeutics, Inc 383
Testing effectiveness (Phase 2)Study completedNCT02066532
What this trial is testing

Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CarcinomaHER-2 Positive Breast Cancer
Dawn L. Hershman 32
Early research (Phase 1)Study completedNCT06253195
What this trial is testing

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorHormone-receptor-positive Breast Cancer+4 more
BeOne Medicines 33
Not applicableNot Yet RecruitingNCT07019272
What this trial is testing

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

Who this might be right for
HER2-positive Breast Cancer
Hebei Medical University Fourth Hospital 170
Next Page